Incyclinide
| Title | Journal |
|---|---|
| Chemically modified tetracycline 3 prevents acute respiratory distress syndrome in a porcine model of sepsis + ischemia/reperfusion-induced lung injury. | Shock (Augusta, Ga.) 20120401 |
| Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase. | Pharmacological research 20111201 |
| Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS). | Pharmacological research 20111201 |
| Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation. | Pharmacological research 20111201 |
| Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas. | Journal of neuro-oncology 20111101 |
| A tetracycline analog improves acute respiratory distress syndrome survival in an ovine model. | The Annals of thoracic surgery 20100801 |
| Matrix metalloproteinase inhibitors reduce collagen gel contraction and alpha-smooth muscle actin expression by periodontal ligament cells. | Journal of periodontal research 20090401 |
| Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. | Inflammation 20090401 |
| Human laminin-332 degradation by Candida proteinases. | Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20080701 |
| A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. | Investigational new drugs 20070801 |
| Chemically modified tetracycline (COL-3) improves survival if given 12 but not 24 hours after cecal ligation and puncture. | Shock (Augusta, Ga.) 20061201 |
| Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. | Endocrine-related cancer 20061201 |
| The immunoglobulin A1 proteinase from Streptococcus pneumoniae is inhibited by tetracycline compounds. | FEMS immunology and medical microbiology 20061101 |
| In vitro inhibition of matrix metalloproteinase activity in tracheal epithelial lining fluid from horses with recurrent airway obstruction. | American journal of veterinary research 20060701 |
| Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. | International journal of cancer 20060301 |
| Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney. | Drug discovery today 20051015 |
| Chemically modified tetracyclines induce apoptosis in cultured mast cells. | International immunopharmacology 20051001 |
| Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. | Shock (Augusta, Ga.) 20051001 |
| [Role of extracellular matrix degradation enzyme for glioma invasion]. | Nihon rinsho. Japanese journal of clinical medicine 20050901 |
| Effect of chemically modified tetracycline on transforming growth factor-beta1 and caspase-3 activation in liver of septic rats. | Critical care medicine 20050701 |
| Tetracycline: from antibiotic to antisepsis. | Critical care medicine 20050701 |
| Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20050701 |
| Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. | International journal of cancer 20050620 |
| A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. | Journal of pharmaceutical and biomedical analysis 20050401 |
| Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. | Pharmaceutical research 20050301 |
| Role of chemically modified tetracycline on TNF-alpha and mitogen-activated protein kinases in sepsis. | Shock (Augusta, Ga.) 20041101 |
| A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. | Clinical cancer research : an official journal of the American Association for Cancer Research 20041001 |
| Transactivator mutants with altered effector specificity allow selective regulation of two genes by tetracycline variants. | Gene 20040428 |
| Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. | Journal of periodontal research 20031201 |
| A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. | The American journal of pathology 20031001 |
| Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. | Journal of clinical pharmacology 20031001 |
| Inhibition of matrix metalloproteinases by chemically modified tetracyclines in sepsis. | Shock (Augusta, Ga.) 20030901 |
| Quantification of 6-deoxy-6-demethyl-4-dedimethylaminotetracycline (COL-3) in human plasma using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030825 |
| Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. | The Journal of surgical research 20030515 |
| Cleaning up the environment. | Drug discovery today 20030201 |
| Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. | Molecular cancer therapeutics 20021101 |
| A chemically modified tetracycline (CMT-3) is a new antifungal agent. | Antimicrobial agents and chemotherapy 20020501 |
| Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. | International journal of cancer 20020310 |
| Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020101 |
| Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. | Journal of periodontology 20020101 |
| Metalloproteinase inhibition prevents acute respiratory distress syndrome. | The Journal of surgical research 20010801 |
| Reversible sideroblastic anemia associated with the tetracycline analogue COL-3. | American journal of hematology 20010501 |
| Drug-induced lupus associated with COL-3: report of 3 cases. | Archives of dermatology 20010401 |
| Development of matrix metalloproteinase inhibitors in cancer therapy. | Journal of the National Cancer Institute 20010207 |
| Biodistribution of radiolabeled [(3)H] CMT-3 in rats. | Current medicinal chemistry 20010201 |
| CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. | Current medicinal chemistry 20010201 |
| Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3). | Current medicinal chemistry 20010201 |
| Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. | Current medicinal chemistry 20010201 |